AJ Lanigan: Yes. Actually, Pharma businesses are building massive income with treatment options like Keytruda and Opdivo that deal with PD-one and PD-L1. Here’s the super cool component: think of checkpoints as traffic alerts. You don’t want an immune process that’s managing wild just like a freight train over a waiting for link from Social Bookmarking (3)